Daoud Al-Badriyeh
Overview
Explore the profile of Daoud Al-Badriyeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abushanab D, Mohamed S, Abdel-Latif R, Moustafa D, Marridi W, Elazzazy S, et al.
Clin Drug Investig
. 2025 Jan;
45(3):151-163.
PMID: 39885055
Background And Objective: While standard doses of adjuvant fluoropyrimidine-based chemotherapies are generally safe for most patients, the risk of severe adverse drug reactions (ADRs) is increased for those with dihydropyrimidine...
2.
Moustafa D, Shafei L, Sulaiman R, Yassin M, Abushanab D, Algarabli Y, et al.
J Oncol Pharm Pract
. 2024 Nov;
31(2):266-275.
PMID: 39569597
IntroductionSeveral meta-analyses (MAs) of the efficacy and safety of daratumumab in refractory/relapsed multiple myeloma (RRMM) exist. They include different types of populations, Daratumumab regimens, and outcomes. Moreover, there is a...
3.
Abushanab D, Mohammed S, Abdel-Latif R, Al-Muftah W, Ismail S, Al Hail M, et al.
J Pharm Policy Pract
. 2024 Oct;
17(1):2410197.
PMID: 39469318
Background: Pharmacogenetic testing improves the efficacy and safety of antidepressant pharmacotherapy for moderate-severe major depressive disorder by identifying genetic variations that influence medication metabolism, and adjusting treatment regimens accordingly. This...
4.
Abushanab D, Al-Badriyeh D, Marquina C, Morton J, Lloyd M, Zomer E, et al.
Eur J Prev Cardiol
. 2024 Sep;
PMID: 39238077
Aims: To quantify the productivity burden of cardiovascular disease (CVD) in type 2 diabetes and the potential benefits of improved CVD risk factor control. Methods: We designed models to quantify...
5.
Kang W, Peng K, Yan V, Al-Badriyeh D, Lee S, Yiu H, et al.
J Pharm Policy Pract
. 2024 Jul;
17(1):2375269.
PMID: 39027009
Background: Direct oral anticoagulants (DOACs) have demonstrated clinical benefits and better patient adherence over low-molecular-weight heparin (LMWH) in treating patients with cancer-associated venous thrombosis (CAT). We aimed to compare the...
6.
Abdel-Latif R, Badji R, Mohammed S, Al-Muftah W, Mbarek H, Darwish D, et al.
Clin Transl Sci
. 2024 May;
17(6):e13800.
PMID: 38818903
Pharmacogenetic (PGx)-informed medication prescription is a cutting-edge genomic application in contemporary medicine, offering the potential to overcome the conventional "trial-and-error" approach in drug prescription. The ability to use an individual's...
7.
Al-Hersh E, Abushanab D, AbouNahia F, Rainkie D, Al Hail M, Abdulrouf P, et al.
J Pharm Policy Pract
. 2024 May;
17(1):2345218.
PMID: 38798766
Objective: Preterm babies are prone to experiencing apnea of prematurity (AOP), mostly characterised by a pause in breathing lasting a minimum of 20 seconds. Recent literature supported higher maintenance doses...
8.
Adel A, Abushanab D, Al-Badriyeh D, Hamad A, Alshurafa A, Yassin M
SAGE Open Med
. 2024 May;
12:20503121231224551.
PMID: 38711465
Objectives: Treatment options for preventing vaso-occlusive crises among sickle cell disease patients are on the rise, especially if hydroxyurea treatment has failed. This economic analysis is conducted to assess the...
9.
Abushanab D, Al-Marridi W, Al Hail M, Abdul Rouf P, Elkassem W, Thomas B, et al.
J Pharm Policy Pract
. 2024 Mar;
17(1):2326382.
PMID: 38549684
Objective: To estimate the economic impact of the developed antimicrobial stewardship program (ASP) versus the preliminary ASP use, in the adults' general medicine settings in Qatar. Methods: Patient records were...
10.
Shafei L, Bashir S, Chan E, Abushanab D, Hamad A, Al-Badriyeh D
Curr Probl Cancer
. 2024 Mar;
50:101076.
PMID: 38537395
Purpose: Selinexor is a first-in-class, oral selective-inhibitor-of-nuclear-export, granted accelerated approval by FDA (2019) for relapsed and refractory multiple myeloma (RRMM). We sought to quantitatively summarize the selinexor efficacy and safety...